Uniphar plc Stock: price and management transactions · United Kingdom · RNS (LSE)

About Uniphar plc

Uniphar plc is an international healthcare services group listed on the London Stock Exchange (FTSE 100/250/AIM) in the United Kingdom, trading under the ticker UPR. The company is headquartered operationally in Dublin, Ireland, and serves customers across Europe, North America, APAC and the Middle East/North Africa region. Its client base includes more than 200 multinational pharmaceutical, biotech and medical technology companies. Uniphar has a long operating history, with the group highlighting more than 55 years of experience, which implies a foundation in the late 1960s. Over time, it has built an integrated healthcare platform spanning several parts of the value chain. The business is structured into three core divisions: Uniphar Pharma, Uniphar Medtech, and Uniphar Supply Chain & Retail. This mix combines higher-value services with distribution-led activities, creating a differentiated model centered on access, compliance, logistics and commercial execution. Uniphar Pharma brings together Access, Medical and Commercial capabilities. These include expanded access programs, medical affairs, regulatory and pharmacovigilance support, market access, launch support, commercial services and distribution. Uniphar Medtech focuses on European medical device distribution and related services, while Uniphar Supply Chain & Retail remains an important platform for pharmaceutical supply chain and retail activities in Ireland. The group does not primarily sell its own branded medicines; instead, it provides critical infrastructure and services that help manufacturers bring products to market and improve patient access. From a competitive standpoint, Uniphar is positioned as a specialist partner for pharma, medtech and biotech companies seeking to manage complex launches, multi-country access requirements and specialist distribution needs. Its value proposition is built around end-to-end service integration and a broad geographic reach, with the company describing operations across more than 160 countries. This makes it a useful partner for innovators that need regulatory, commercial and supply chain support rather than a pure-play wholesaler. Recent developments reinforce that strategic direction. In 2025, Uniphar rebranded its On Demand business as Uniphar | Global Sourcing, sharpening its global pharmaceutical sourcing platform and extending its capabilities through strategically located facilities in the US and Europe. In 2026, the group also announced an exclusive European distribution agreement for LYMPHIR™ with Citius Oncology, underscoring its role in facilitating access to complex therapies and supporting international commercialization pathways. For investors, Uniphar is best viewed as a healthcare services and distribution specialist with defensive characteristics, exposed to the structural growth of outsourced pharma services, specialty distribution and access solutions in the United Kingdom-listed market on the London Stock Exchange (FTSE 100/250/AIM).